97 related articles for article (PubMed ID: 24673720)
41. Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice.
Ye J; Shao H; Hickman D; Angel M; Xu K; Cai Y; Song H; Fouchier RA; Qin A; Perez DR
Clin Vaccine Immunol; 2010 Sep; 17(9):1363-70. PubMed ID: 20668143
[TBL] [Abstract][Full Text] [Related]
42. Regulatory roles of c-jun in H5N1 influenza virus replication and host inflammation.
Xie J; Zhang S; Hu Y; Li D; Cui J; Xue J; Zhang G; Khachigian LM; Wong J; Sun L; Wang M
Biochim Biophys Acta; 2014 Dec; 1842(12 Pt A):2479-88. PubMed ID: 24780373
[TBL] [Abstract][Full Text] [Related]
43. Risk assessment of recent Egyptian H5N1 influenza viruses.
Arafa AS; Yamada S; Imai M; Watanabe T; Yamayoshi S; Iwatsuki-Horimoto K; Kiso M; Sakai-Tagawa Y; Ito M; Imamura T; Nakajima N; Takahashi K; Zhao D; Oishi K; Yasuhara A; Macken CA; Zhong G; Hanson AP; Fan S; Ping J; Hatta M; Lopes TJ; Suzuki Y; El-Husseiny M; Selim A; Hagag N; Soliman M; Neumann G; Hasegawa H; Kawaoka Y
Sci Rep; 2016 Dec; 6():38388. PubMed ID: 27922116
[TBL] [Abstract][Full Text] [Related]
44. Effects of immunoglobulin upon murine myocarditis caused by influenza A virus: superiority of intact type to F(ab')2 type.
Kishimoto C; Hiraoka Y; Takada H
J Cardiovasc Pharmacol; 2004 Jan; 43(1):61-7. PubMed ID: 14668569
[TBL] [Abstract][Full Text] [Related]
45. In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2.
Racine T; Denizot M; Pannetier D; Nguyen L; Pasquier A; Raoul H; Saluzzo JF; Kobinger G; Veas F; Herbreteau CH
J Infect Dis; 2019 Jun; 220(1):41-45. PubMed ID: 30852585
[TBL] [Abstract][Full Text] [Related]
46. PA-X-associated early alleviation of the acute lung injury contributes to the attenuation of a highly pathogenic H5N1 avian influenza virus in mice.
Hu J; Mo Y; Gao Z; Wang X; Gu M; Liang Y; Cheng X; Hu S; Liu W; Liu H; Chen S; Liu X; Peng D; Liu X
Med Microbiol Immunol; 2016 Aug; 205(4):381-95. PubMed ID: 27289459
[TBL] [Abstract][Full Text] [Related]
47. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
Wang X; Ni B; Du X; Zhao G; Gao W; Shi X; Zhang S; Zhang L; Wang D; Luo D; Xing L; Jiang H; Li W; Jiang M; Mao L; He Y; Xiao Y; Wu Y
Antivir Ther; 2005; 10(5):681-90. PubMed ID: 16152762
[TBL] [Abstract][Full Text] [Related]
48. Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1).
WHO/OIE/FAO H5N1 Evolution Working Group
Emerg Infect Dis; 2008 Jul; 14(7):e1. PubMed ID: 18598616
[TBL] [Abstract][Full Text] [Related]
49. Pre-Treatment with Zirconia Nanoparticles Reduces Inflammation Induced by the Pathogenic H5N1 Influenza Virus.
Huo C; Xiao J; Xiao K; Zou S; Wang M; Qi P; Liu T; Hu Y
Int J Nanomedicine; 2020; 15():661-674. PubMed ID: 32099358
[TBL] [Abstract][Full Text] [Related]
50. Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.
Marathe BM; Wong SS; Vogel P; Garcia-Alcalde F; Webster RG; Webby RJ; Najera I; Govorkova EA
Sci Rep; 2016 May; 6():26742. PubMed ID: 27221530
[TBL] [Abstract][Full Text] [Related]
51. Dose-response time modelling for highly pathogenic avian influenza A (H5N1) virus infection.
Kitajima M; Huang Y; Watanabe T; Katayama H; Haas CN
Lett Appl Microbiol; 2011 Oct; 53(4):438-44. PubMed ID: 21790679
[TBL] [Abstract][Full Text] [Related]
52. Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments.
Ramisse F; Deramoudt FX; Szatanik M; Bianchi A; Binder P; Hannoun C; Alonso JM
Clin Exp Immunol; 1998 Mar; 111(3):583-7. PubMed ID: 9528903
[TBL] [Abstract][Full Text] [Related]
53. Improving siRNA design targeting nucleoprotein gene as antiviral against the Indonesian H5N1 virus.
Hartawan R; Pujianto DA; Dharmayanti NLPI; Soebandrio A
J Vet Sci; 2022 Mar; 23(2):e24. PubMed ID: 35187881
[TBL] [Abstract][Full Text] [Related]
54. Contribution of Fc fragment of monoclonal antibodies to tetanus toxin neutralization.
Ghotloo S; Amiri MM; Khoshnoodi J; Abbasi E; Jeddi-Tehrani M; Golsaz-Shirazi F; Shokri F
Neurotox Res; 2020 Mar; 37(3):578-586. PubMed ID: 31721050
[TBL] [Abstract][Full Text] [Related]
55. The protective effect of a combination of human intracellular and extracellular antibodies against the highly pathogenic avian influenza H5N1 virus.
Jin Q; Yao Z; Liu F; Di Y; Gao J; Zhang X
Hum Vaccin Immunother; 2022 Dec; 18(1):2035118. PubMed ID: 35240918
[TBL] [Abstract][Full Text] [Related]
56. Anti-endotoxin monoclonal antibodies protect by enhancing bacterial and endotoxin clearance.
Burd RS; Cody CS; Raymond CS; Dunn DL
Arch Surg; 1993 Feb; 128(2):145-50; discussion 150-1. PubMed ID: 7679267
[TBL] [Abstract][Full Text] [Related]
57. Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse.
Yan Y; Liu Q; Li N; Du J; Li X; Li C; Jin N; Jiang C
Sci China Life Sci; 2015 Feb; 58(2):208-11. PubMed ID: 25655897
[No Abstract] [Full Text] [Related]
58. Equine immunoglobulin fragment F(ab')
Gupta D; Ahmed F; Tandel D; Parthasarathy H; Vedagiri D; Sah V; Krishna Mohan B; Khan RA; Kondiparthi C; Savari P; Jain S; Reddy S; Kumar JM; Khan N; Harshan KH
Clin Immunol; 2022 Apr; 237():108981. PubMed ID: 35306171
[TBL] [Abstract][Full Text] [Related]
59. Construction of a chimeric secretory IgA and its neutralization activity against avian influenza virus H5N1.
Li C; An X; Butt AM; Zhang B; Zhang Z; Wang X; Huang Y; Zhang W; Zhang B; Mi Z; Tong Y
J Immunol Res; 2014; 2014():394127. PubMed ID: 24741594
[TBL] [Abstract][Full Text] [Related]
60. Immunomorphologic manifestations in mice liver infected with influenza A/H5N1, A/goose/Krasnoozerskoye/627/05 strain.
Potapova OV; Sharkova TV; Shkurupiy VA; Shestopalov AM
Clin Dev Immunol; 2013; 2013():342686. PubMed ID: 24454472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
